Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00727506 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00727506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00727506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
July 14, 2008
Completion date
May 25, 2016
Enrollment
151 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

glioma